Histopathological profile of ovarian tumors at a tertiary care center of Nepal
DOI:
https://doi.org/10.3126/jpn.v15i2.90639Keywords:
Alpha-fetoprotein, CA-125 Antigen, Germ Cell Tumor, Human Chorionic Gonadotropin-beta, Ovarian Cancer, Tumor MarkersAbstract
Background: Ovarian tumors encompass a diverse group of neoplasms, including both benign and malignant forms with distinct clinical and histological features. In Nepal, ovarian cancer was the 10th most common cancer in 2022, with 643 new cases, representing 2.9% of all newly diagnosed cancers. Histopathological examination remains the definitive method for identifying and classifying ovarian tumors into benign, borderline, and malignant categories. This study aimed to determine the histopathological patterns of ovarian masses and examine their association with serum tumor markers.
Materials and Methods: This is a cross-sectional descriptive study conducted over 2 years in the Department of Pathology at Paropakar Maternity and Women’s Hospital, Thapathali, Kathmandu, which included 319 patients who underwent ovarian biopsies. Histopathological examination was performed post-surgery and the descriptive evaluation of various histopathological subtype were conducted.
Results: Among 319 cases of ovarian specimens, the majority of ovarian masses were benign, 292 cases (91.54%), malignant tumors, 21 cases (6.58%), and borderline tumors, 6 cases (1.88%). Mean age of patients presenting with benign tumors was 32 years, while it was 33 years for malignant tumors, and 51 years for borderline tumors.
Conclusions: The majority of ovarian tumors are benign, with germ cell tumors, particulartly mature cystic teratomas being the most frequent histopathological subtype. Histopathological examination remains the definite gold standard for tumor classification.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.